argenx announces closing of global offering
Regulated information
Author Archives: admin
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to fourteen new employees with grant date of February 1, 2021, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
View post:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
See more here:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment.
Excerpt from:
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium Announces Closing of $30 Million Registered Direct Offering
LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.
Read more here:
Equillium Announces Closing of $30 Million Registered Direct Offering
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure – GuruFocus.com
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ("UKE") for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.
Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure. Heart failure is frequently associated with ischemic heart disease and often comes with a poor prognosis. Mortality is comparable to that of the most common cancers, with <50% 4-year survival. Treatment of patients suffering from heart failure is expected to deliver significant patient benefit through improved heart function, ultimately leading to an improved prognosis.
Evotec leverages its industry-leading human induced pluripotent stem cells ("hiPSCs") platform to establish GMP-compatible process development and upscaling for large-scale generation of clinical-grade heart muscle cells known as cardiomyocytes. Evotec will also contribute genetically modified GMP iPSC lines, which contain alterations preventing rejection of the cardiomyocyte-containing product by patient immune systems ("cloaking"), and include additional safety mechanisms to control unwanted proliferation of graft cells. By using these GMP-grade iPSC lines, the project will deliver off-the-shelf products, which can be implanted in broad patient populations with little to no immunosuppression. UKE applies its proprietary Giga Patch Method for the generation of fully functional heart tissue suitable for cardiac transplantation. Further in vivo validation and development activities will be shared jointly between the partners. Evotec will be responsible for GMP and pre-clinical activities as well as for any subsequent partnering of the programme.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this collaboration with the UKE. Both Evotec and UKE have developed and refined their respective technology platforms over a number of years and have now decided to jointly drive this cardiac cell therapy programme towards clinical development. We are confident that this partnership will deliver a new therapeutic option for patients who suffer from heart failure."
Prof. Dr Thomas Eschenhagen, Director of the Institute of Experimental Pharmacology and Toxicology at UKE, added: "We are excited about the new opportunities the partnership with Evotec will create. After having worked on means to repair injured heart by 3-dimensional heart muscle patches for over two decades, joining forces with Evotec and its industrialized hiPSC platform and new cell lines, will bring this development to a new stage. We are aiming at the most efficient and safest therapy in the field."
"We are very happy to see a scientific success story advance to a feat of technology transfer. Translation of scientific insights into therapeutic options is a key mission of our University Medical Center", says Prof. Dr Blanche Schwappach-Pignataro, the Dean of Faculty of Medicine of the UKE.
No financial terms of the agreement were disclosed.
About heart failure Heart failure is a severe global health burden with more than 26 million people suffering with the condition worldwide, disproportionately affecting elderly people. While there are options to treat heart failure both medicinally and with devices, there is currently no treatment that targets the cause of the disease or significantly slows down its progression.
About Evotec and iPSC Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company's proprietary EVOcells platform.
ABOUT THE MEDICAL CENTER HAMBURG-EPPENDORF (UKE) Since its foundation in 1889, the Medical Center Hamburg-Eppendorf (UKE) has been one of the leading clinics in Europe. With about 13,600 employees, the UKE is one of the largest employers in Hamburg. Each year, the UKE treats around 511,000 patients, 106,000 of whom are inpatients and 405,000 outpatients. The emphasis in UKE's research are the neurosciences, cardiovascular research, care research, oncology, as well as infections and inflammations. Other potential areas of the UKE are molecular imaging and skeletal biology research. The UKE trains about 3,400 medical specialists and dentists. Knowledge, Research, Healing through Shared Competence: The UKE | http://www.uke.de
ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.
FORWARD-LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Media Contact Evotec SE: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, [emailprotected]
IR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [emailprotected]
SOURCE: Evotec AG
View source version on accesswire.com: https://www.accesswire.com/627865/Evotec-and-Medical-Center-Hamburg-Eppendorf-Enter-Partnership-to-Develop-iPSC-Based-Tissue-Therapy-for-Heart-Failure
Read the original here:
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - GuruFocus.com
Researchers curb local immune response in horses receiving stem cell injury therapy – Horsetalk
Cultures with treated stem cells had a 50% higher stem cell survival rate than untreated cultures. Image by carolem41
Treating equine donor stem cells with a growth factor called TGF-2 may allow them to avoid tripping the immune response in recipients, according to new research.
The work carried out at North Carolina State University could simplify the stem cell treatment process for ligament and tendon injuries in horses, and may also have implications for human stem cell therapies.
Mesenchymal stem cell therapy is a promising avenue for treating musculoskeletal injuries, particularly tendon and ligament injuries, in horses.
Mesenchymal stem cells are adult stem cells found in bone marrow that act as repair directors, producing secretions that recruit healing-related paracrine factors to the site of injury.
Just as blood cells have types, depending upon which antigens are on the blood cells surface, mesenchymal stem cells have differing sets of major histocompatibility complex molecules, or MHCs, on their surfaces.
If the MHCs of donor and recipient arent a match, the donors stem cells cause an immune response. In organ transplants, MHCs are carefully matched to prevent rejection.
These treatments arent like a bone marrow transplant or an organ transplant, says Lauren Schnabel, associate professor of equine orthopedic surgery at the university and corresponding author of the study, reported in the journal Frontiers in Cell and Developmental Biology.
Since the mesenchymal stem cells are being used temporarily to treat localized injury, researchers once thought that they didnt need to be matched that they wouldnt cause an immune response. Unfortunately, that isnt the case.
Schnabel and Alix Berglund, a research scholar at the university and lead author of the paper, wanted to find a way to use mesenchymal stem cell therapy without the time, effort and additional cost of donor/recipient matching.
Since these cells dont have to be in the body as long as an organ does, hiding them from the immune system long enough for them to secrete their paracrine factors could be a way around donor/recipient matching, Berglund says. Downregulating expression of the MHC molecules could be one way to do this.
The researchers cultured stem cells and lymphocytes, or T cells, from eight horses, cross-pairing them in vitro so that the stem cells and lymphocytes had differing MHC haplotypes.
In one group, stem cells had been treated with transforming growth factor beta (TGF-2) prior to being added to the lymphocytes in the culture media; the other group was untreated. TGF-2 is a cell-signaling molecule produced by white blood cells that blocks immune responses.
Cultures with treated stem cells had a 50% higher stem cell survival rate than untreated cultures.
We use mesenchymal stem cells to treat musculoskeletal injuries particularly tendon injuries in horses very effectively, Schnabel says.
And while you can extract the secretions from the stem cells, you get better results with the cells themselves. Stem cells arent just a reservoir of secretions, theyre a communications hub that tells other cells what they should be doing. So finding a way to utilize these cells without stimulating immune response gives us better treatment options.
This is a promising pilot study, Berglund says. Our next steps will be to further explore the immune response in vivo, and to look at human cells in vitro, as this work has excellent potential to help humans with these injuries as well.
The research was supported by the National Institutes of Health and the Morris Animal Foundation. Research specialist Julie Long and statistician James Robertson, both with the university, also contributed to the work.
TGF-b2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties Alix K. Berglund, Julie M. Long, James B. Robertson, Lauren V. Schnabel Cell Dev. Biol., 04 February 2021 https://doi.org/10.3389/fcell.2021.628382
The study, published under a Creative Commons License, can be read here.
Read the rest here:
Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk
Biobanking Market Report Research and Global Outlook 2021 to 2025 KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper
A New Research report Biobanking Market has been recently added to the Market Insights Reports database. The report offers definitive information pertaining to the commercialization aspects, revenue estimation, and market size of the industry. The report defines the status of key players in the competitive landscape including their portfolio and geographical expansion pursuits. This report also focuses on Biobanking Market Trend, volume, and value at the global level, regional level, and company level.
According to this study, over the next five years the Biobanking market will register a 6.0% CAGR in terms of revenue, the global market size will reach $ 3381 million by 2025, from $ 2676.4 million in 2019.
The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.Top Companiesin the Global Biobanking Market:Beckman Coulter, Tecan Group, Thermo Fisher, Sigma-Aldrich, SOL Group, Panasonic, Brooks Life Science, Promega, QIAGEN, BD, Askion, Cryo Bio System, Biolife Solutions, Lifeline Scientific, DNA Genotek, LVL Technologies, Micronic, So-Low, BioRep and Others.
Click the link to get a free Sample Copy of the Report:
Market Overview:
The major factors for the growth of the global biobanks market include the innovations in regenerative medicine, the growing incidence of chronic diseases, advances in drug discovery and development, and R&D funding and investments by government and non-governmental organizations. These factors are expected to a boost the growth of the market over the forecast period.
Regenerative medicine through stem cell technology is one of the important treatments for diseases, such as Alzheimers, diabetes, cancers, and rare genetic diseases. In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved.
Stem cell practices are on the rise, globally, and are contributing to the development of new solutions for various diseases. Boston-based biotech start-up, Orig3n, is looking to build the largest and most diverse biobank, harnessing the power of induced pluripotent stem cell technology to accelerate regenerative medicine. Treatments for diseases, like muscular degeneration, using adult stem cells are now going into Phase 3 clinical trials in Japan. These successes are driving both the government and the private sector organizations into investing in more stem cell banks.
With the increase in awareness about stem cell therapies, there have been larger number of parents who are choosing umbilical cord banks for their children. There are a number of donor banks that are coming up as well. Biobanks not only aid in the therapies for genetic diseases, but also in medical research on rare genetic disorders. Increasing awareness about stem cell therapies and innovation in the field of regenerative medicine are driving the growth of the global biobank market.
This report segments the Global Biobanking Market on the basis ofTypesare:
Equipment Consumable
On the basis ofApplication,the Global Biobanking Market is segmented into:
Virtual Biobanks Tissue Biobanks Population Biobanks
Top Line Market Forecast:
Both Regional and Global sectors are included in the Outlook, with special breakouts for the NAM, European, MENA, and Asia-Pacific regions. The data covered is from 2015 to 2019 historically and from 2021 to 2025 forecast, it also includes the impact of Covid-19 both on the short- and long-term prospects of the industry.
Full Browse the report description and TOC:
Detailed overview of Market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Biobanking Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth
The research includes historic data from 2015 to 2021 and forecasts until 2025 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.
Purchase Full Report@:
https://www.marketinsightsreports.com/report/purchase/10292408158?mode=su?Mode=A28
Customization of the Report: The report can be further customized according to the clients specific research requirements. No additional charges will be added for limited additional research.
Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.
MarketInsightsReportsprovides syndicated market research on industry verticals includingHealthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact Us: Biobanking
Irfan Tamboli (Head of Sales) Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com|irfan@marketinsightsreports.com
Continued here:
Biobanking Market Report Research and Global Outlook 2021 to 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Animal Stem Cell Therapy Market By Product Type (Dogs, Horses) And By End-Users/Application (Veterinary Hospitals, Research Organizations) Market…
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. Animal Stem Cell Therapy Market size has covered and analyzed the potential of Worldwide market Industry and provides statistics and information on market dynamics, market analysis, growth factors, key challenges, major drivers & restraints, opportunities and forecast. This report presents a comprehensive overview, market shares, and growth opportunities of market 2028 by product type, application, key manufacturers and key regions and countries.
The recently released report byResearch N Reportstitled as Animal Stem Cell Therapy Market is a detailed analogy that gives the reader an insight into the intricacies of the various elements like the growth rate, and impact of the socio-economic conditions that affect the market space. An in-depth study of these numerous components is essential as all these aspects need to blend-in seamlessly for businesses to achieve success in this industry.
The report includes profiles of leading companies in the Animal Stem Cell Therapy market. Some of the key players profiled include:
The following manufacturers are covered in this report: Aratana Therapeutics Cell Therapy Sciences VETSTEM BIOPHARMA Magellan Stem Cells U.S. Stem Cell VetCell Therapeutics J-ARM Animal Care Stem ANIMAL CELL THERAPIES Cells Power Japan MediVet Biologic Animacel Celavet
Animal Stem Cell Therapy Market Segmentation: The report offers in-depth analysis of the Animal Stem Cell Therapy market based on various segments such as type, application and end-use industry. The Animal Stem Cell Therapy market is segmented as follows:
Animal Stem Cell Therapy Market, by Type:
Animal Stem Cell Therapy Market, by Application:
Get Download Pdf Sample Copy of this Report- https://www.researchnreports.com/request_sample.php?id=71511
The research report includes company Competitors top sellers profiles, their data, deals income, revenue share, deal volume, and purchaser volume are equally specified. The conclusions provided in this report are of great value for the leading industry players. Every organization partaking in the global production of the Animal Stem Cell Therapy products have been mentioned in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications. The report is molded by tracking market performance since 2015 and is one of the most detailed reports.
Based on Region
Ask for Discount on this Premium Report https://www.researchnreports.com/ask_for_discount.php?id=71511
Reasons Why You Should Buy This Report
This report provides pin-point analysis for changing competitive dynamics
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Inquire or share your questions if any before the purchasing this report https://www.researchnreports.com/enquiry_before_buying.php?id=71511
Table of Contents:
Read Report Overview https://www.researchnreports.com/pharma-healthcare/Global-Animal-Stem-Cell-Therapy-Market-71511
About Us:
Research N Reports:
Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer-driven market, companies require information to deal with the complex and dynamic world of choices, where relying on a soundboard firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cutthroat competition. Since we excel at business research to help businesses grow, we also offer to consult as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently, we keep evolving as an all-rounder provider of viable information under one roof.
Contact:
Sunny Denis (Sales Manager), (Research N Reports) 10916, Gold Point Dr, Houston, TX, Pin 77064, +1-510-420-1213, sales@researchnreports.com https://www.researchnreports.com/
Read this article:
Animal Stem Cell Therapy Market By Product Type (Dogs, Horses) And By End-Users/Application (Veterinary Hospitals, Research Organizations) Market...
Stem Cell Assay Market Share, Demand, Manufacturers and Forecast till 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent…
The Report Titled on Stem Cell Assay Market which provides COVID19 Impact analysis on Market Size (Production, Capacity, Value, Values & Consumption), Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis, Impact of Domestic and Market Players. Stem Cell Assay Market detailed study of historical and present/future market data. Economic growth, GDP (Gross Domestic Product), and inflation are some of the elements included in this report to offer crystal clear picture of the Stem Cell Assay industry at global level.
Stem Cell Assay Market competitive landscapes provides details by topmost manufactures like (Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.
Request for a Sample Report of Stem Cell Assay Market:https://www.coherentmarketinsights.com/insight/request-sample/1632
Market Segmentation & Coverage:
This research report categorizes the Stem Cell Assay to forecast the revenues and analyze the trends in each of the following sub-markets:
By Product Type-InstrumentsReagents & KitsBy Cell Type Adult Stem CellsInduced Pluripotent Stem CellsMesenchymal Stem CellsNeural Stem CellsHematopoietic Stem CellsUmbilical Cord Stem CellsHuman Embryonic Stem CellsBy Process Cell CultureEngineeringDifferentiationCharacterizationOthersBy Application -ResearchDrug Discovery & DevelopmentRegenerative Medicine
Based on Geography, the Stem Cell Assay Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Impact of COVID-19 on this Market:
The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.
We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
The Stem Cell Assay Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window:
Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Apply Promo Code STAYHOME and Get Up to 30% Discount
If you purchase the report this year:
Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/1632
The report provides insights on the following pointers:
Market Penetration: Provides comprehensive information on the market offered by the key players
Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
What is the market size and forecast of the Global Stem Cell Assay Market?
What are the inhibiting factors and impact of COVID-19 shaping the Global Stem Cell Assay Market during the forecast period?
Which are the products/segments/applications/areas to invest in over the forecast period in the Global Stem Cell Assay Market?
What is the competitive strategic window for opportunities in the Global Stem Cell Assay Market?
What are the technology trends and regulatory frameworks in the Global Stem Cell Assay Market?
What are the modes and strategic moves considered suitable for entering the Global Stem Cell Assay Market?
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us
Mr. Shah 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 sales@coherentmarketinsights.com
Continue reading here:
Stem Cell Assay Market Share, Demand, Manufacturers and Forecast till 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent...